Darbepoetin alfa is a lab-made version of a hormone that stimulates the body to make more red blood cells. It belongs to a class of medicines called erythropoiesis-stimulating agents (ESAs), used to treat anaemia caused by chronic kidney disease or certain cancer chemotherapy. It is a prescription-only medicine that carries a boxed warning.

• Therapeutic Class: Anti-anaemia medicine (erythropoiesis-stimulating agent).

• Pharmacological Class: Erythropoiesis-stimulating agent, erythropoietin analog.

• Drug Family: Recombinant erythropoietin derivatives.

• ATC Classification: B03XA02 (Darbepoetin alfa).

Approved: Anaemia due to chronic kidney disease (CKD), including patients on dialysis and those not on dialysis; anaemia in patients with non-myeloid cancers where the anaemia is caused by concurrent myelosuppressive chemotherapy.

Commonly used for: Patients with CKD-related anaemia needing fewer transfusions, and cancer patients on chemotherapy with anaemia significant enough to require treatment.

Off-label use (only under medical guidance): Not typically used off-label; ESAs carry significant safety warnings that limit use strictly to approved settings.

● Injection (single-dose vial/prefilled syringe): commonly available in 25 mcg, 40 mcg, 60 mcg, 100 mcg, and 200 mcg strengths.

Normally, the kidneys produce a hormone called erythropoietin in response to low oxygen levels, which signals the bone marrow to make more red blood cells. In chronic kidney disease, this natural production is impaired, and in chemotherapy, red blood cell production can also be suppressed. Darbepoetin alfa acts like this natural hormone, stimulating the bone marrow to produce more red blood cells and reduce anaemia.

• Standard dose (CKD): Individualised based on hemoglobin levels and clinical response, typically starting at a low dose and adjusted based on regular hemoglobin monitoring, given weekly, every 2 weeks, or monthly depending on the CKD/dialysis setting.

• Condition-wise dose (chemotherapy-related anaemia): Also individualised and adjusted based on hemoglobin response; discontinued following completion of the chemotherapy course.

• Route: Subcutaneous or intravenous injection, depending on the clinical setting.

• Missed dose: Rescheduled by the treating clinical team based on the dosing interval in use.

• Overdose: Can lead to excessively high hemoglobin levels, increasing clotting risk; managed with dose withholding and close monitoring.

• Common: High blood pressure, injection-site reactions, and joint/muscle pain.

• Serious: Increased risk of death, serious cardiovascular events, blood clots, and — in cancer patients — a possible increased risk of tumour progression or recurrence when hemoglobin targets are set too high (boxed warning).

• Emergency symptoms: Chest pain, sudden weakness or numbness on one side of the body, sudden shortness of breath, leg swelling or pain, or signs of a severe allergic reaction.

• Recovery advice: Regular hemoglobin monitoring allows the dose to be adjusted to use the lowest effective amount, which is central to managing the cardiovascular and clotting risks associated with this class of medicines.

• Pregnancy: Used only if clearly needed, under medical supervision.

• Breastfeeding: Used with medical guidance; specific safety data are limited.

• Liver disease: Used with caution and monitoring.

• Kidney disease: This is one of the medicine's primary approved uses; dosing is tailored to CKD stage and dialysis status.

• Elderly: Commonly used in this age group; monitored for cardiovascular risk factors.

• Children: Used in some pediatric CKD settings under specialist guidance.

● Other ESAs: not combined with other erythropoiesis-stimulating agents.

● Iron supplements: often needed alongside darbepoetin alfa — a supportive combination, not an interaction to avoid.

● Medicines affecting blood pressure: darbepoetin alfa can raise blood pressure, so interactions are monitored closely.

● Anticoagulants: increased hemoglobin/red cell mass alongside blood-thinning medicines requires attention to overall clotting risk balance.

● Hemoglobin levels regularly, to keep within the target range and avoid overcorrection.

● Blood pressure monitoring.

● Iron studies (iron, ferritin, transferrin saturation) to ensure adequate iron stores.

● Assessment for signs of blood clots or cardiovascular symptoms throughout treatment.

Epoetin alfa (a related, shorter-acting erythropoiesis-stimulating agent); blood transfusion, as a non-pharmacological alternative.

Often used alongside iron supplementation, since ESAs work best when iron stores are adequate; not combined with other ESAs.

● Anaemia Medicines

● Chronic Kidney Disease Supportive Care

● Erythropoiesis-Stimulating Agents

1. 7 Unexpected Warning Signs of Iron Deficiency

2. Low Haemoglobin: Sign, Symptoms, Causes & Treatment

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951orig1s5173_103951orig1s5258lbl.pdf

• https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9&type=pdf
  

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.